Law360
ADVERTISEMENT
Hikma Should Face Amarin s Patent Suit, Magistrate Says
Law360 (August 3, 2021, 8:54 PM EDT) Hikma Pharmaceuticals should not be able to dodge a lawsuit claiming it encouraged doctors to prescribe its generic version of the heart drug Vascepa for uses covered by a series of Amarin patents, a Delaware federal magistrate judge says.
Magistrate Judge Jennifer L. Hall on Tuesday issued a report and recommendation in a lawsuit filed by Amarin Pharma Inc., Amarin Pharmaceuticals Ireland Ltd. and Mochida Pharmaceutical Co. Ltd. alleging that Hikma induced infringement of three patents.
Specifically, Amarin alleged in the so-called skinny label case that Hikma induced doctors to infringe the patents by instructing them to use the Hikma generic.
CBD And Hemp Legal And Regulatory Roundup – July 16, 2021 - Cannabis & Hemp
mondaq.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mondaq.com Daily Mail and Mail on Sunday newspapers.
Viewpoint: Candidates starting to line up for fall municipal elections
uptownmessenger.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from uptownmessenger.com Daily Mail and Mail on Sunday newspapers.
A federal magistrate judge has recommended against shifting nearly $690,000 in fees and expenses to Pfizer unit Anacor Pharmaceuticals from a company that challenged Anacor's patent for a toenail fungus treatment, citing an absence of evidence that Anacor pursued unreasonable infringement claims or patent defenses.